Pharma robotics company Multiply Labs closes $75 million Series B with AstraZeneca participating

Multiply Labs has closed a $75 million Series B round with participation from AstraZeneca and other industrial investors, bringing cumulative funding past $100 million. The company uses modular robot clusters compatible with pharmaceutical companies' existing equipment for automated biopharmaceutical production such as cell therapies, and claims it can cut manufacturing costs by 74% and raise output per unit area by up to 100 times, though most of its new directions remain at the project validation stage. The article also compares the differing business approaches of Cellular Origins and Cellares, and notes that Multiply Labs uses imitation learning and NVIDIA's digital twin platform to capture expert operating experience.